MicroRNAs are small molecules that modulate the expression of most genes and so affect nearly every biological process and pathology although, they were only discovered in humans less than 10 years ago. The bottleneck in discovering the functions of miRNAs is in identifying their molecular targets, the majority of which remain unknown. We aim to comprehensively identify direct target genes of epithelial-specific microRNAs and to confirm a number of them by gene target validation approaches.
Role Of The MiR-200 Target Quaking In Alternative Splicing During EMT And Cancer Progression
Funder
National Health and Medical Research Council
Funding Amount
$443,160.00
Summary
The spread of cancer to other organs involves cancer cells changing to a more aggressive state and is a major cause of cancer related death. MicroRNAs are a class of genes that control whether cancer cells become more aggressive by regulating other genes. In this project we will examine the function of a new microRNA target which controls the cancer cell aggression. The outcome will be a better understanding of how cancers spread and the identification of new therapeutic targets.
Mab Immunotherapies For Myeloid Leukemia Patients With Germline Or Somatic RUNX1 Mutations.
Funder
National Health and Medical Research Council
Funding Amount
$766,995.00
Summary
This proposal presents preliminary evidence and proposes to confirm that 2 cell surface molecules, CD11a (ITGAL) and IL3RA (CD123) are direct (probably repression) targets of RUNX1 in HSCs, and are dysregulated in RUNX1 mutated AML. Monoclonal antibody therapies that target these two surface molecules have already passed different clinical trial phases for different diseases. We plan to show these antibodies are effective in RUNX1 positive AML in preclinical models and then clinical trials.
Targeting MicroRNA-driven Mesenchymal To Epithelial Transition To Suppress Prostate Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$741,831.00
Summary
Prostate cancer kills ~3,000 men per year in Australia. The development of metastasis is the major cause of prostate cancer-associated death and has limited treatment options. In this study, we will characterise the role of a group of molecules, termed microRNAs, in prostate cancer metastasis. We will also test whether targeting microRNAs using novel drugs termed antagomiRs is an effective strategy to inhibit metastasis and thereby improve prostate cancer mortality.
Characterising Novel Alternative Splicing Networks That Promote Tumour Cell Plasticity
Funder
National Health and Medical Research Council
Funding Amount
$609,329.00
Summary
During cancer progression, tumour cells can change their properties and become more aggressive and resistant to therapies. We have identified an important regulator of this tumour cell transition, called “Quaking”, which causes widespread changes in gene splicing. We aim to investigate how "Quaking" causes changes in gene splicing and what the effects of these splicing changes are in tumour cells.
Industrial Transformation Training Centres - Grant ID: IC170100016
Funder
Australian Research Council
Funding Amount
$3,123,492.00
Summary
ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therap ....ARC Training Centre for Personalised Therapeutics Technologies. The ARC Training Centre for Personalised Therapeutics Technologies aims to create and develop the skills and technology to benefit from the transformative impacts that cell/organ-on-a-chip technology will have on the medtech/pharma industries. By combining microfluidics-based/real-time technologies with personalised medicine the Training Centre will provide industry growth opportunities through improved screening of potential therapeutics. The use of an individual patient’s cellular and molecular research findings will ultimately enable personalised diagnostic and therapeutic decisions.Read moreRead less
Unveiling the epigenome dynamics through the pluripotency continuum. This project aims to utilise stem cells and genomics based technologies, in combination with new computational algorithms to dissect the fundamental molecular events that drive the first steps during development. The project is expected to unveil the basic mechanisms underpinning how genes driving the developmental master plan are controlled in cells that have the capacity to give rise to the whole organism and placenta. The kn ....Unveiling the epigenome dynamics through the pluripotency continuum. This project aims to utilise stem cells and genomics based technologies, in combination with new computational algorithms to dissect the fundamental molecular events that drive the first steps during development. The project is expected to unveil the basic mechanisms underpinning how genes driving the developmental master plan are controlled in cells that have the capacity to give rise to the whole organism and placenta. The knowledge gained from this work will inform and guide future novel approaches, such as in assisted reproductive technologies or regenerative medicine.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC190100026
Funder
Australian Research Council
Funding Amount
$4,969,663.00
Summary
ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway an ....ARC Training Centre for Cell and Tissue Engineering Technologies. The ARC Training Centre for Cell and Tissue Engineering Technologies aims to provide training to create a highly skilled workforce for the tissue engineering and regenerative medicine sector and to enhance research performance and innovation in Australia through fundamental and applied research carried out in industry-led PhD projects. The research aims to address major aspects of the manufacturing and commercialisation pathway and barriers faced by the sector, namely improving process efficiencies, enabling early-stage scale-up (cell/tissue) and development of the sector's supply chain. The knowledge created and research undertaken would help to accelerate commercialisation in regenerative medicine, tissue engineering and cell therapies.Read moreRead less
Brain Repair Following Stroke: The Role Of Npas4, A Neural-specific Transcription Factor
Funder
National Health and Medical Research Council
Funding Amount
$611,053.00
Summary
Stroke is the #1 cause of adult disability in Australia and #2 cause of death. About 60,000 Australians suffer a stroke each year while about 250,000 live with the disabilities of stroke, costing over $2B/year. The Queen Elizabeth Hospital and University of Adelaide will study why the Npas4 gene switches on after stroke and the role it plays in brain repair. Future health benefits may be tests to help improve stroke outcome in patients and therapy to decrease loss of brain cells after stroke.
Understanding How GATA2 Controls Lymphatic Vessel Valve Development
Funder
National Health and Medical Research Council
Funding Amount
$697,942.00
Summary
Mutations in the GATA2 gene cause human lymphoedema as a result of the crucial role that GATA2 plays in controlling the expression of genes important for building functional lymphatic vessels. Here we aim to gain a complete picture of the cellular and molecular events that are controlled by GATA2 in lymphatic vessels and in particular, in lymphatic vessel valves.